Home »
news
We can deliver more breakthroughs in women's health — starting now.
1
Women experience health issues differently, disproportionately, and uniquely.
99% of studies
on the biology of
aging fail to consider menopause.
A transition that affects half the world’s population.
Women
account for
80% of patients
with autoimmune diseases.
Which are chronic and, in many cases, debilitating.
Simply being
a woman
doubles
the risk of
dementia.
We do not know why.
Cardiovascular disease is the leading cause of death for women globally.
Yet we know little about what drives differences in disease development and progression between women and men.
2
We are chronically underinvested in women’s health research.
In 2020, less than 2% of $471.4B in philanthropy directly benefitted women and girls.
And less than 0.3% went to women’s health.
In 2023, less than 10% of NIH’s $48.4B budget was focused on women’s health.
Low levels of funding relative to other areas means top scientific talent is not attracted or retained to work on women’s health issues.
The lack of research in women’s health is felt in the real lives of billions of women: girls miss school, women spend 25% more of their lives in poor health compared to men1. They are held back from thriving and exercising their power. It is a fundamental barrier to equity and social progress.
Women’s health conditions are treated like medical mysteries, instead of solvable problems that we can diagnose and treat — if only we invest
in the research needed to do so.
We have the power to change this.
We can generate breakthroughs in years, not decades.
3
Closing the women’s health gap is a moral and economic imperative.
Closing the women’s health gap could inject more than $1 Trillion into the global economy annually by 2040.
Today’s global women’s health gap equates to 75M years of life lost due to poor health or early death.
Investing in women’s health shows positive return on investment: for every $1 invested, approximately $3 of growth is projected.
Wellcome Leap announces breakthrough in funded project at Caltech: points to new all-in-one vaccine for SARS-like betacoronaviruses – Phase I clinical trials initiated by CEPI.
July 5, 2022
Share this work
Image courtesy of Wellcome Leap, Caltech, and Merkin Institute.
© 2022. All rights reserved.
Los Angeles – July 5, 2022: Wellcome Leap, a U.S. based non-profit organization founded by the Wellcome Trust to accelerate and increase the number of breakthroughs in global health, today announced a significant advance by researchers in the Bjorkman lab at Caltech. The study demonstrates broad immune responses in non-human primates against a spectrum of SARS-like betacoronaviruses when immunized with a new nanoparticle-based vaccine, named mosaic-8.
The key to this advance is the specific construct of the vaccine, which aims to elicit an immune response to the parts of the viral spike that do not change between variants or between animal SARS-like betacoronaviruses strains – a so-called ‘conserved’ part of the spike.
This advance suggests that it may be possible to be vaccinated against animal viruses that could spill over to infect humans to cause another pandemic and also against SARS-CoV-2 variants before they even exist. The core nanoparticle technology was initially developed by collaborators at the University of Oxford and has been further optimized to achieve broad protection in the Bjorkman lab in this study.
The current work builds on earlier Bjorkman lab experiments, supported by Caltech’s Merkin Institute for Translational Research, that demonstrated broad immune responses in mice against SARS-like betacoronaviruses (Cohen et al, 2021). The new study, sponsored by Wellcome Leap, established protection from a SARS-CoV-2 Delta variant challenge in non-human primates (representing protection for a ‘mismatched’ variant since the SARS-CoV-2 Beta variant was presented in the mosaic-8 construct, but the Delta variant was not). Importantly, as published today in Science, the vaccine also showed protection from SARS-CoV, a different strain of betacoronavirus, which was also not presented in the mosaic-8 nanoparticle, thereby demonstrating the potential to provide protection against an as-yet-unknown SARS-like betacoronavirus that could spill over into humans. Wellcome Leap’s agile funding model provided the pivotal support needed to achieve these milestones and, importantly, to maintain the scientific momentum catalyzed by Merkin’s funding of the Bjorkman lab.
“We couldn’t have done this research this quickly without Wellcome Leap. Period,” Dr. Pamela Bjorkman said. “Leap approached us at a critical juncture of our research and provided us with the funding to allow us to expand into testing in non-human primates. They also helped us clear obstacles and build effective collaborations. I estimate they reduced our timeline from two years to six months, which in lab timelines is unheard of. I am incredibly proud of the work the team did on this and we are looking forward to phase I clinical trials to evaluate our vaccine candidate, which will be funded by CEPI.”
Image courtesy of Wellcome Leap, Caltech, and Merkin Institute.
© 2022. All rights reserved.
With animals showing little to no detectable infection when exposed to either ‘matched’ or ‘unmatched’ SARS-like strains, this nanoparticle development has the potential to mitigate viral infection caused by known and future variants of the class of virus that caused the current global pandemic, but also to mitigate potential pandemics caused by future viral spill overs within the SARS-like betacoronavirus family.
“This outcome demonstrates the priority we put on stacking the odds in favor of a breakthrough – we believe that we can accelerate and increase the number of breakthroughs if we work with speed, agility, and global collaboration,” said Dr. Regina E. Dugan, CEO of Wellcome Leap. “By matching the high potential of the research with a high sense of urgency, we may now be in a better position on pandemic prevention.”
As a result of these findings, the Bjorkman lab has formed a consortium led by UK deep tech innovation organization CPI and secured up to $30 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for Phase 1 clinical trials of the mosaic-8 vaccine. The overall acceleration has the potential to condense the path to full-scale production by three to four years.
“We have talked about the need for diversity in vaccine development since the very beginning of the pandemic,” said Dr. Richard J. Hatchett, CEO of CEPI. “The breakthrough exhibited in the Bjorkman lab study demonstrates huge potential for a strategy that pursues a new vaccine platform altogether, potentially overcoming hurdles created by new variants. I am delighted to announce that CEPI will be supporting this novel approach to pandemic prevention in Phase I clinical trials.
The accelerated speed the study achieved after receiving Wellcome Leap funding facilitated our relationship with them today. The non-human primate data is extremely encouraging and we’re excited to support the next phase of trials.”
This announcement comes two months after Wellcome Leap announced an additional $335M in new funding, with the organization now having over half a billion dollars at work. All Wellcome Leap programs aim to deliver breakthroughs in human health over 5 – 10 years and demonstrate seemingly impossible results on seemingly impossible timelines. Complementary to the five programs in action, the Wellcome Leap Program Seedling budget is used to support projects that demonstrate high breakthrough potential or could become programs in and of themselves.
About Wellcome Leap
Wellcome Leap builds and executes bold, unconventional programs, funded at scale. Programs that aim to deliver breakthroughs in human health over 5 – 10 years. Founded by the Wellcome Trust in 2020 as a US nonprofit with initial funding of $300 million, Leap programs target complex human health challenges with the goal of achieving breakthrough scientific and technological solutions. Operating at the intersection of life sciences and engineering, Leap programs require best-in-class, multi-disciplinary, global teams assembled from universities, companies, and nonprofits working together to solve problems that they cannot solve alone.
With an additional $335 million in funding from the Wellcome Trust, the organization now has over half a billion dollars at work.
For more information on Wellcome Leap, please visit www.wellcomeleap.org or follow us on Twitter and LinkedIn.
About the Merkin Institute
Caltech’s Merkin Institute for Translational Research provided some of the initial funding to develop the mosaic-8 nanoparticles.
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus – it has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).
During the current pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19 as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation to these vaccines worldwide through COVAX.
CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a universal vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at https://endpandemics.cepi.net.
Follow our news page for the latest updates. Follow us via @CEPIvaccines, @DrRHatchett, and LinkedIn.
About CPI
CPI takes great ideas and inventions and makes them a reality. Born in the North East of England in 2004, CPI is an independent deep tech innovation organisation and a founding member of the High Value Manufacturing Catapult.
CPI’s team of intelligent people use advances in science and technology to solve the biggest global challenges in healthcare and sustainability. Through incredible people and innovation infrastructure, CPI collaborates with partners in industry, academia, government, and the investment community to accelerate the development and commercialisation of innovative products.
CPI’s work ranges from health technologies, advanced drug delivery systems, and medicines manufacturing innovations for multiple modalities including small molecules, biologics, and nucleic acids; to developing sustainable materials for energy storage and packaging, as well as novel food, feed, and nutraceuticals, that are all underpinned by digital technology. CPI turns the entrepreneurial spirit and radical thinking of its people and partners into incredible impact that makes our world a better place.
Let’s innovate together: uk-cpi.com
Connect with us: LinkedIn Twitter Instagram Facebook
Wellcome Leap announces over $300M in additional funding.
Now more than Half a Billion Dollars for catalyzing breakthroughs in human health.
February 2, 2022
Share this work
Image shows kidney tissue constructed from organoid building blocks by Jennifer Lewis (Harvard) and Ryuji Morizane (MGH) labs. The ultimate goal is to create tissues that can restore sufficient function to free patients from dialysis.
Los Angeles – Feb. 2, 2022: Wellcome Leap (Leap), a U.S. based non-profit organization founded by the Wellcome Trust to accelerate breakthroughs for global health, has today announced an additional $335M in new funding. Combined with the $300M allocated at launch, the organization will have well over half a billion dollars at work.
The COVID-19 pandemic brought human health and the threat of disease into a focus not seen in modern history. In one of the greatest scientific accomplishments of our generation, mRNA technology has demonstrated the ability to change the timeline for developing and delivering a new vaccine from years to months. And the entire world was witness to that demonstration.
“The last 2 years have laid bare how much work we have to do in health, equity, and care for the planet. They have also revealed the difference a breakthrough makes,” said CEO, Dr. Regina E. Dugan. “We need more breakthroughs to solve the urgent challenges facing the world. And we need them faster.”
The Wellcome Trust recently announced its biggest funding commitment to science and health in its 85-year history. It plans to raise charitable spending to £16 billion (over $21.5 billion) over the next decade to fund science that supports a healthy future for everyone. It has also committed an extra £750 million (over $1 billion) to fund large-scale, high-impact activities across five years, which they anticipate will grow to £1 billion next year.
Dr. Jeremy Farrar, Director of Wellcome said: “Support for long-term, basic science is vital. We founded Wellcome Leap because we also need to ensure that somewhere in the system there is a truly disruptive element that can take bigger risks, challenge the consensus point of view, and work globally to find the best talent and ideas to push forward. We expect to allocate about 5% of our funding into the future to Wellcome Leap as a complement to our other investments. Since its inception, Wellcome Leap has hit the ground running with ambitious programs that seek to deliver transformative results from mRNA production to mental health and physiology. Bold initiatives like these are key to maintaining the momentum of the last two years. We couldn’t be more delighted, or impressed, with the work to date.”
Jay Flatley, Chair of Wellcome Leap, said “What Wellcome Leap has achieved in less than two years has exceeded all our expectations and is on par with the best execution I’ve seen in any commercial setting. The assembly of this unicorn leadership team is one of Wellcome Leap’s most important accomplishments – they are inspiring, outcome focused, and uniquely qualified to take on the challenge.”
All Wellcome Leap programs aim to deliver breakthroughs in human health over 5 – 10 years and demonstrate seemingly impossible results on seemingly impossible timelines. To do so, programs have ambitious goals that are also testable and measurable – the setting of the bar for a program is among the hardest things we do. It requires Program Directors who are scientifically accomplished and who dare to ask ‘what if?’ They formulate the program and serve as conductors of a global, dynamic network of performers working together to solve problems they cannot solve alone.
But an ambitious goal is not enough. We have to change the boundary conditions of the work itself. Wellcome Leap is optimized for breakthroughs – this requires speed, agility, and changes across all dimensions of operation, selection, and execution to systematically increase the probability of success.
Wellcome Leap has funded 5 programs that aim to create 10X improvements in three dimensions: increase understanding of human health and disease, transform economics, and increase the speed, scale and equity of access. All programs are focused on achieving tangible gains that demonstrate at convincing scale the ability to overcome some of the most challenging threats to human health from depression, brain development, and infectious diseases to the platforms needed to transform drug development, production, and access.
About Wellcome Leap Wellcome Leap builds and executes bold, unconventional programs, funded at scale. Programs that aim to deliver breakthroughs in human health over 5 – 10 years. Founded by the Wellcome Trust in 2020 as a US nonprofit with initial funding of $300 million, Leap programs target complex human health challenges with the goal of achieving breakthrough scientific and technological solutions. Operating at the intersection of life sciences and engineering, Leap programs require best-in-class, multi-disciplinary, global teams assembled from universities, companies, and nonprofits working together to solve problems that they cannot solve alone.
With an additional $335 million in funding from the Wellcome Trust, the organization now has over half a billion dollars at work.
Los Angeles – Feb. 2, 2022: Wellcome Leap (Leap), a U.S. based non-profit organization founded by the Wellcome Trust to accelerate breakthroughs for global health, has today announced an additional $335M in new funding. Combined with the $300M allocated at launch, the organization will have well over half a billion dollars at work.
The COVID-19 pandemic brought human health and the threat of disease into a focus not seen in modern history. In one of the greatest scientific accomplishments of our generation, mRNA technology has demonstrated the ability to change the timeline for developing and delivering a new vaccine from years to months. And the entire world was witness to that demonstration.
“The last 2 years have laid bare how much work we have to do in health, equity, and care for the planet. They have also revealed the difference a breakthrough makes,” said CEO, Dr. Regina E. Dugan. “We need more breakthroughs to solve the urgent challenges facing the world. And we need them faster.”
The Wellcome Trust recently announced its biggest funding commitment to science and health in its 85-year history. It plans to raise charitable spending to £16 billion (over $21.5 billion) over the next decade to fund science that supports a healthy future for everyone. It has also committed an extra £750 million (over $1 billion) to fund large-scale, high-impact activities across five years, which they anticipate will grow to £1 billion next year.
Dr. Jeremy Farrar, Director of Wellcome said: “Support for long-term, basic science is vital. We founded Wellcome Leap because we also need to ensure that somewhere in the system there is a truly disruptive element that can take bigger risks, challenge the consensus point of view, and work globally to find the best talent and ideas to push forward. We expect to allocate about 5% of our funding into the future to Wellcome Leap as a complement to our other investments. Since its inception, Wellcome Leap has hit the ground running with ambitious programs that seek to deliver transformative results from mRNA production to mental health and physiology. Bold initiatives like these are key to maintaining the momentum of the last two years. We couldn’t be more delighted, or impressed, with the work to date.”
Jay Flatley, Chair of Wellcome Leap, said “What Wellcome Leap has achieved in less than two years has exceeded all our expectations and is on par with the best execution I’ve seen in any commercial setting. The assembly of this unicorn leadership team is one of Wellcome Leap’s most important accomplishments – they are inspiring, outcome focused, and uniquely qualified to take on the challenge.”
All Wellcome Leap programs aim to deliver breakthroughs in human health over 5 – 10 years and demonstrate seemingly impossible results on seemingly impossible timelines. To do so, programs have ambitious goals that are also testable and measurable – the setting of the bar for a program is among the hardest things we do. It requires Program Directors who are scientifically accomplished and who dare to ask ‘what if?’ They formulate the program and serve as conductors of a global, dynamic network of performers working together to solve problems they cannot solve alone.
But an ambitious goal is not enough. We have to change the boundary conditions of the work itself. Wellcome Leap is optimized for breakthroughs – this requires speed, agility, and changes across all dimensions of operation, selection, and execution to systematically increase the probability of success.
Wellcome Leap has funded 5 programs that aim to create 10X improvements in three dimensions: increase understanding of human health and disease, transform economics, and increase the speed, scale and equity of access. All programs are focused on achieving tangible gains that demonstrate at convincing scale the ability to overcome some of the most challenging threats to human health from depression, brain development, and infectious diseases to the platforms needed to transform drug development, production, and access.
About Wellcome Leap Wellcome Leap builds and executes bold, unconventional programs, funded at scale. Programs that aim to deliver breakthroughs in human health over 5 – 10 years. Founded by the Wellcome Trust in 2020 as a US nonprofit with initial funding of $300 million, Leap programs target complex human health challenges with the goal of achieving breakthrough scientific and technological solutions. Operating at the intersection of life sciences and engineering, Leap programs require best-in-class, multi-disciplinary, global teams assembled from universities, companies, and nonprofits working together to solve problems that they cannot solve alone.
With an additional $335 million in funding from the Wellcome Trust, the organization now has over half a billion dollars at work.
Share this work